Is Aarti Pharmalabs the Best Stock in Its Sector? A Look at the Numbers
- September 16, 2026
- Posted by: Harsh Piplani
- Category: Market
Aarti Pharmalabs CMP Rs 813 (16 Sep 2026). Market cap Rs 7,157 Cr. ROE 8.89%. P/E 34.39x versus Industry P/E 51.01x.
Quick Answer
Aarti Pharmalabs is one of the names investors compare when screening the Chemicals sector, built on a 8.89% return on equity and a P/E of 34.39x against an Industry P/E of 51.01x. Whether Aarti Pharmalabs is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Chemicals sector peers, so you can judge that for yourself.
Is Aarti Pharmalabs the best stock in its sector? The stock trades on the NSE at Rs 813 as of 16 September 2026, within its 52-week range of Rs 585.00 to Rs 946.10. Aarti Pharmalabs Ltd manufactures pharmaceutical intermediates, active pharmaceutical ingredients and xanthine derivatives, supplying pharma customers in India and export markets.
Aarti Pharmalabs sits in the Chemicals sector, and its 8.89% ROE and 34.39x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Aarti Pharmalabs
Aarti Pharmalabs Ltd manufactures pharmaceutical intermediates, active pharmaceutical ingredients and xanthine derivatives, supplying pharma customers in India and export markets. It was demerged from Aarti Industries in 2023 to separate the pharmaceutical intermediates business from Aarti’s broader chemicals operations. At a market capitalisation of Rs 7,157 Cr, it is tracked as part of the Chemicals sector on Univest.
Is Aarti Pharmalabs the Best Stock in Its Sector?
Aarti Pharmalabs makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 8.89% ROE with a 34.39x P/E against the sector’s 51.01x Industry P/E. Aarti Pharmalabs’ 34.39x P/E is well below the 51.01x Industry P/E, and its 8.89% ROE is a reasonable figure for a recently demerged pharma intermediates business still establishing its standalone track record.
| Metric | Aarti Pharmalabs |
|---|---|
| CMP (NSE) | Rs 813.00 |
| 52-Week High / Low | Rs 946.10 / Rs 585.00 |
| Market Cap | Rs 7,157 Cr |
| P/E (TTM) vs Industry P/E | 34.39x vs 51.01x |
| P/B | 3.61 |
| ROE | 8.89% |
| EPS (TTM) | Rs 22.95 |
| Dividend Yield | 0.44% |
| Debt to Equity | 0.38 |
Compare Aarti Pharmalabs Against Other Chemicals Sector Stocks
How Aarti Pharmalabs Compares Against Its Chemicals Sector Peers
The table below sets Aarti Pharmalabs against 3 other Chemicals sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 3 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Aarti Pharmalabs | 7,157 | 34.39 | 8.89% | 0.38 |
| Galaxy Surfactants | 7,758 | 21.93 | 9.74% | 0.09 |
| Fine Organic Industries | 15,825 | 36.12 | 15.65% | 0.03 |
| Sumitomo Chemical India | 22,536 | 38.89 | 16.02% | 0.02 |
| Peer average (3 companies) | – | 32.31 | 13.80% | 0.05 |
Against this peer set, Aarti Pharmalabs’s 8.89% ROE is below the 13.80% peer average, and its P/E of 34.39x runs above the peer average of 32.31x. Aarti Pharmalabs’ 34.39x P/E is well below the 51.01x Industry P/E, and its 8.89% ROE is a reasonable figure for a recently demerged pharma intermediates business still establishing its standalone track record.
What Makes Aarti Pharmalabs Worth Watching in Chemicals
- Below Industry P/E: A 34.39x P/E against a 51.01x Industry P/E is a discount for a pharma intermediates manufacturer.
- Focused pharma intermediates business: A dedicated pharmaceutical intermediates and API manufacturing focus followed its 2023 demerger from Aarti Industries.
- Moderate leverage: A debt to equity ratio of 0.38 is manageable for a chemicals manufacturer funding capacity expansion.
Aarti Pharmalabs Valuation: Is It Justified?
Aarti Pharmalabs’ 34.39x P/E is well below the 51.01x Industry P/E, and its 8.89% ROE is a reasonable figure for a recently demerged pharma intermediates business still establishing its standalone track record. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is Bata India the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Aarti Pharmalabs and other Chemicals sector stocks.
How to Track Aarti Pharmalabs Before You Invest
Before deciding whether Aarti Pharmalabs deserves its label as the best stock in its sector for your own portfolio, compare it directly against Chemicals sector peers using the steps below.
- Open the Univest Screener and search for Aarti Pharmalabs to view live price, valuation ratios, and peer comparisons within the Chemicals sector.
- Compare its P/E, P/B, and ROE against other Chemicals sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Aarti Pharmalabs earns a place in the best stock in its sector conversation on the strength of a 8.89% ROE and a P/E of 34.39x against a 51.01x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Aarti Pharmalabs the best stock in its sector?
Ans. Aarti Pharmalabs has a 8.89% ROE and trades at 34.39x P/E against a 51.01x Industry P/E, and compares below the peer average ROE of 13.80% in this article’s named comparison, so the answer depends on what an investor is prioritising.
What is the current share price of Aarti Pharmalabs?
Ans. Aarti Pharmalabs was trading at Rs 813.00 on the NSE as of 16 September 2026, within its 52-week range of Rs 585.00 to Rs 946.10.
What sector does Aarti Pharmalabs belong to?
Ans. Aarti Pharmalabs is classified under the Chemicals sector on Univest.
How does Aarti Pharmalabs compare to its sector peers on P/E?
Ans. Aarti Pharmalabs’s P/E of 34.39x is above the 32.31x average of the 3 named peers compared in this article.
What is Aarti Pharmalabs’s return on equity?
Ans. Aarti Pharmalabs reported a return on equity of 8.89%, which is below the 13.80% average of its named peers in this comparison.
Should I invest in Aarti Pharmalabs based on its sector position?
Ans. Aarti Pharmalabs’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.
